Cargando…

Coping with Viral Diversity in HIV Vaccine Design

The ability of human immunodeficiency virus type 1 (HIV-1) to develop high levels of genetic diversity, and thereby acquire mutations to escape immune pressures, contributes to the difficulties in producing a vaccine. Possibly no single HIV-1 sequence can induce sufficiently broad immunity to protec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickle, David C, Rolland, Morgane, Jensen, Mark A, Pond, Sergei L. Kosakovsky, Deng, Wenjie, Seligman, Mark, Heckerman, David, Mullins, James I, Jojic, Nebojsa
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857809/
https://www.ncbi.nlm.nih.gov/pubmed/17465674
http://dx.doi.org/10.1371/journal.pcbi.0030075
_version_ 1782133166693154816
author Nickle, David C
Rolland, Morgane
Jensen, Mark A
Pond, Sergei L. Kosakovsky
Deng, Wenjie
Seligman, Mark
Heckerman, David
Mullins, James I
Jojic, Nebojsa
author_facet Nickle, David C
Rolland, Morgane
Jensen, Mark A
Pond, Sergei L. Kosakovsky
Deng, Wenjie
Seligman, Mark
Heckerman, David
Mullins, James I
Jojic, Nebojsa
author_sort Nickle, David C
collection PubMed
description The ability of human immunodeficiency virus type 1 (HIV-1) to develop high levels of genetic diversity, and thereby acquire mutations to escape immune pressures, contributes to the difficulties in producing a vaccine. Possibly no single HIV-1 sequence can induce sufficiently broad immunity to protect against a wide variety of infectious strains, or block mutational escape pathways available to the virus after infection. The authors describe the generation of HIV-1 immunogens that minimizes the phylogenetic distance of viral strains throughout the known viral population (the center of tree [COT]) and then extend the COT immunogen by addition of a composite sequence that includes high-frequency variable sites preserved in their native contexts. The resulting COT(+) antigens compress the variation found in many independent HIV-1 isolates into lengths suitable for vaccine immunogens. It is possible to capture 62% of the variation found in the Nef protein and 82% of the variation in the Gag protein into immunogens of three gene lengths. The authors put forward immunogen designs that maximize representation of the diverse antigenic features present in a spectrum of HIV-1 strains. These immunogens should elicit immune responses against high-frequency viral strains as well as against most mutant forms of the virus.
format Text
id pubmed-1857809
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-18578092007-04-28 Coping with Viral Diversity in HIV Vaccine Design Nickle, David C Rolland, Morgane Jensen, Mark A Pond, Sergei L. Kosakovsky Deng, Wenjie Seligman, Mark Heckerman, David Mullins, James I Jojic, Nebojsa PLoS Comput Biol Research Article The ability of human immunodeficiency virus type 1 (HIV-1) to develop high levels of genetic diversity, and thereby acquire mutations to escape immune pressures, contributes to the difficulties in producing a vaccine. Possibly no single HIV-1 sequence can induce sufficiently broad immunity to protect against a wide variety of infectious strains, or block mutational escape pathways available to the virus after infection. The authors describe the generation of HIV-1 immunogens that minimizes the phylogenetic distance of viral strains throughout the known viral population (the center of tree [COT]) and then extend the COT immunogen by addition of a composite sequence that includes high-frequency variable sites preserved in their native contexts. The resulting COT(+) antigens compress the variation found in many independent HIV-1 isolates into lengths suitable for vaccine immunogens. It is possible to capture 62% of the variation found in the Nef protein and 82% of the variation in the Gag protein into immunogens of three gene lengths. The authors put forward immunogen designs that maximize representation of the diverse antigenic features present in a spectrum of HIV-1 strains. These immunogens should elicit immune responses against high-frequency viral strains as well as against most mutant forms of the virus. Public Library of Science 2007-04 2007-04-27 /pmc/articles/PMC1857809/ /pubmed/17465674 http://dx.doi.org/10.1371/journal.pcbi.0030075 Text en © 2007 Nickle et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Nickle, David C
Rolland, Morgane
Jensen, Mark A
Pond, Sergei L. Kosakovsky
Deng, Wenjie
Seligman, Mark
Heckerman, David
Mullins, James I
Jojic, Nebojsa
Coping with Viral Diversity in HIV Vaccine Design
title Coping with Viral Diversity in HIV Vaccine Design
title_full Coping with Viral Diversity in HIV Vaccine Design
title_fullStr Coping with Viral Diversity in HIV Vaccine Design
title_full_unstemmed Coping with Viral Diversity in HIV Vaccine Design
title_short Coping with Viral Diversity in HIV Vaccine Design
title_sort coping with viral diversity in hiv vaccine design
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857809/
https://www.ncbi.nlm.nih.gov/pubmed/17465674
http://dx.doi.org/10.1371/journal.pcbi.0030075
work_keys_str_mv AT nickledavidc copingwithviraldiversityinhivvaccinedesign
AT rollandmorgane copingwithviraldiversityinhivvaccinedesign
AT jensenmarka copingwithviraldiversityinhivvaccinedesign
AT pondsergeilkosakovsky copingwithviraldiversityinhivvaccinedesign
AT dengwenjie copingwithviraldiversityinhivvaccinedesign
AT seligmanmark copingwithviraldiversityinhivvaccinedesign
AT heckermandavid copingwithviraldiversityinhivvaccinedesign
AT mullinsjamesi copingwithviraldiversityinhivvaccinedesign
AT jojicnebojsa copingwithviraldiversityinhivvaccinedesign